Malignant mesothelioma with unexpected contralateral mediastinal shift: a case report

por Myerson, James S, Nicum, Shibani, Sharma, Bhupinder, O'Brien, Mary ER
Publicado 2008

Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol

por Mansouri, Anita, McGregor, Naomi, Dunn, Rachel, Dobbie, Sam, Holmes, Jane, Collins, Linda, Nicum, Shibani
Publicado 2021

A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol

por Nicum, Shibani, Roberts, Corran, Boyle, Lucy, Kopijasz, Sylwia, Gourley, Charlie, Hall, Marcia, Montes, Ana, Poole, Christopher, Collins, Linda, Schuh, Anna, Dutton, Susan J
Publicado 2014

Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours

por Roberts, Corran, Strauss, Victoria Y., Kopijasz, Sylwia, Gourley, Charlie, Hall, Marcia, Montes, Ana, Abraham, Jacinta, Clamp, Andrew, Kennedy, Richard, Banerjee, Susana, Folkes, Lisa K., Stratford, Michael, Nicum, Shibani
Publicado 2019

c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial

por Morgan, Robert D., Ferreras, Cristina, Peset, Isabel, Avizienyte, Egle, Renehan, Andrew G., Edmondson, Richard J., Murphy, Alexander D., Nicum, Shibani, Van Brussel, Thomas, Clamp, Andrew R., Lambrechts, Diether, Zhou, Cong, Jayson, Gordon C.
Publicado 2022

Impact of Multiple COVID-19 Waves on Gynaecological Cancer Services in the UK

por Oxley, Samuel, Kalra, Ashwin, Sideris, Michail, Itzkowitz, Nicole, Evans, Olivia, Atakpa, Emma Christine, Brentnall, Adam R., Dworschak, Nina, Gaba, Faiza, Gabe, Rhian, Sundar, Sudha, Wood, Nick, Nicum, Shibani, Taylor, Alexandra, Dobbs, Stephen, McCluggage, W. Glenn, Nordin, Andy, Legood, Rosa, Kehoe, Sean, Ghaem-Maghami, Sadaf, Manchanda, Ranjit
Publicado 2023

British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian Cancer

por Sundar, Sudha, Nordin, Andy, Morrison, Jo, Wood, Nick, Ghaem-Maghami, Sadaf, Nieto, Jo, Phillips, Andrew, Butler, John, Burton, Kevin, Gornall, Rob, Dobbs, Stephen, Glasspool, Rosalind, Peevor, Richard, Ledermann, Jonathan, McNeish, Iain, Ratnavelu, Nithya, Duncan, Tim, Frost, Jonathan, Lim, Kenneth, Michael, Agnieszka, Brockbank, Elly, Gajjar, Ketankumar, Taylor, Alexandra, Bowen, Rebecca, Andreou, Adrian, Ganesan, Raji, Nicum, Shibani, Edmondson, Richard, Clayton, Richard, Balega, Janos, Rolland, Phil, Maxwell, Hilary, Fotopoulou, Christina
Publicado 2023

Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor-initiating cells

por Artibani, Mara, Masuda, Kenta, Hu, Zhiyuan, Rauher, Pascal C., Mallett, Garry, Wietek, Nina, Morotti, Matteo, Chong, Kay, KaramiNejadRanjbar, Mohammad, Zois, Christos E., Dhar, Sunanda, El-Sahhar, Salma, Campo, Leticia, Blagden, Sarah P., Damato, Stephen, Pathiraja, Pubudu N., Nicum, Shibani, Gleeson, Fergus, Laios, Alexandros, Alsaadi, Abdulkhaliq, Santana Gonzalez, Laura, Motohara, Takeshi, Albukhari, Ashwag, Lu, Zhen, Bast, Robert C., Harris, Adrian L., Ejsing, Christer S., Klemm, Robin W., Yau, Christopher, Sauka-Spengler, Tatjana, Ahmed, Ahmed Ashour
Publicado 2021